Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
Thomas GaillardJeanne PikettyJean-Guillaume FeronNoemie GirardLea PaulyElodie GauroyLauren DarriguesBeatriz GrandalJean-Yves PiergaAnne-Sophie Hamy-PetitFabien ReyalEnora LaasPublished in: British journal of cancer (2024)
The MonarchE trial may significantly affect surgical practices due to the need for invasive procedures to identify high-risk patients for adjuvant abemaciclib treatment. The prospect of unnecessary morbidity demands less invasive N2 status determination methods. Surgical decisions must consider patient health and potential treatment benefits.
Keyphrases
- healthcare
- clinical trial
- ejection fraction
- end stage renal disease
- study protocol
- phase iii
- lymph node
- primary care
- newly diagnosed
- early stage
- randomized controlled trial
- phase ii
- mental health
- prognostic factors
- radiation therapy
- neoadjuvant chemotherapy
- high resolution
- combination therapy
- current status
- replacement therapy
- risk assessment
- patient reported outcomes
- patient reported
- ultrasound guided
- health promotion